However, another anti-interleukin-6 receptor (IL-6R) molecule, anakinra, an IL-1 receptor antagonist, appears useful in CRS prevention and other neurotoxicities that may not be treated by tocilizumab. The gene discussed is IL6R; the disease is congenital rubella syndrome.